Due to the direct relationship between the acetylcholine (ACh), a parasympathetic neurotransmitter, deficit and the severity of dementia, AD is preferentially treated with acetylcholinesterase (AChE) inhibitors. This evidence concerns the gene ACHE and Alzheimer disease.